Loading company…
Vaxinano develops nasal vaccines and immunotherapies for infectious and zoonotic diseases.
Vaxinano develops nasal vaccines and immunotherapies using a nanoparticle delivery system intended to cross mucosal barriers without adjuvants. Its work addresses pathogens including parasites, viruses and bacteria, and includes veterinary programs with 24 zoos worldwide. Founded in 2016 by CEO Didier Betbeder, the company is based in Loos, France. On October 10, 2024, it raised EUR 6.000 mn in seed funding from Bpifrance Investissement, Captech Health Nutrition, Nord France Amorçage, TCD Capital and Wiseed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in